Antares Announces Commercial Availability Of XYOSTED Injection

(RTTNews) - Antares Pharma Inc. (ATRS) announced the availability of XYOSTED or testosterone enanthate injection.

XYOSTED is the only FDA approved subcutaneous testosterone product for once-weekly, at-home self-administration with an easy-to-use, single dose, disposable QuickShot auto injector.

XYOSTED has been approved in three dosage strengths, 50 mg, 75 mg and 100 mg and is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

XYOSTED was approved by the U.S. Food and Drug Administration on September 28, 2018.

The company warned that XYOSTED can cause blood pressure increases that can increase the risk for major adverse cardiovascular events (MACE), including non-fatal myocardial infarction, non-fatal stroke and cardiovascular death, with greater risk for MACE in patients with cardiovascular risk factors or established cardiovascular disease.

The company advised that use XYOSTED only for the treatment of men with hypogonadal conditions associated with structural or genetic etiologies.

XYOSTED or testosterone enanthate injection is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.